Email this article 
Comparison of harvesting methods and clinical application of apheresis platelet concentrates with additive solution
- Authors: Karpova O.V.1,2, Obraztsov I.V.1,2, Trakhtman P.E.1,2, Ignatova A.A.1,2, Panteleev M.A.1,3,4,5, Rumyantsev S.A.1,6,7,8
-
Affiliations:
- Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia
- 1 Samory Mashela St., Moscow, 117198, Russia
- 1 Samory Mashela St., Moscow, 117198, Russia Theoretical Problems Center of Physical and Chemical Pharmacology, Russian Academy of Sciences
- 38A, Bldg. 1 Leninskiy Prosp., Moscow, 119991, Russia M.V. Lomonosov Moscow State University
- 1 Leninskie Gory St., Moscow, 119234, Russia
- 1 Samory Mashela St., Moscow, 117198, Russia N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
- 1 Ostrovityanova St., Moscow, 117997, Russia Moscow Institute of Physics and Technology (State University)
- 9 Institutskiy per., Dolgoprudnyy, Moscow Region, Russia, 141700
- Issue: Vol 10, No 2 (2015)
- Pages: 63-68
- Section: BASIC RESEARCH
- Published: 04.06.2015
- URL: https://oncohematology.abvpress.ru/ongm/article/view/147
- DOI: https://doi.org/10.17650/1818-8346-2015-10-2-63-68
- ID: 147
Cite item
Full Text
Abstract
Platelet concentrates (PC) are used worldwide in the fields of oncology, oncohaematology and bone marrow transplantation. One of the main tasks of clinical transfusiology is the development and improvement of technologies aimed to increase quality and safety of PC. In particular, such technologies are represented by using of platelet additive solutions (PAS). The main advantages of this approach are: a reduction of immune and non-immune transfusion reactions risk, an improvement of pathogen inactivation quality and enhancing a clinical effect of PC transfusions after storage. Numerous different PAS and methodologies of their application are suggested to date. In this review we have described and classified recent data on different PAS and the benefits of their clinical application.
Keywords
About the authors
O. V. Karpova
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, Russia
Author for correspondence.
Email: ovk_67@mail.ru
Russian Federation
I. V. Obraztsov
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, RussiaRussian Federation
P. E. Trakhtman
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, RussiaRussian Federation
A. A. Ignatova
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, RussiaRussian Federation
M. A. Panteleev
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, RussiaTheoretical Problems Center of Physical and Chemical Pharmacology, Russian Academy of Sciences; 38A, Bldg. 1 Leninskiy Prosp., Moscow, 119991, Russia
M.V. Lomonosov Moscow State University; 1 Leninskie Gory St., Moscow, 119234, Russia
Russian Federation
S. A. Rumyantsev
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117198, RussiaN.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; 1 Ostrovityanova St., Moscow, 117997, Russia
Moscow Institute of Physics and Technology (State University); 9 Institutskiy per., Dolgoprudnyy, Moscow Region, Russia, 141700
Russian Federation
References
Supplementary files
